- Home
- INAB vs EQ Comparison
INAB vs EQ Comparison
Compare INAB & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INAB
- EQ
- Stock Information
- Founded
- INAB 2016
- EQ 2017
- Country
- INAB United States
- EQ United States
- Employees
- INAB N/A
- EQ N/A
- Industry
- INAB Biotechnology: Pharmaceutical Preparations
- EQ Biotechnology: Pharmaceutical Preparations
- Sector
- INAB Health Care
- EQ Health Care
- Exchange
- INAB Nasdaq
- EQ Nasdaq
- Market Cap
- INAB 14.5M
- EQ 13.1M
- IPO Year
- INAB 2021
- EQ 2018
- Fundamental
- Price
- INAB $2.16
- EQ $0.39
- Analyst Decision
- INAB Strong Buy
- EQ Buy
- Analyst Count
- INAB 2
- EQ 3
- Target Price
- INAB $108.00
- EQ $3.00
- AVG Volume (30 Days)
- INAB 151.7K
- EQ 576.7K
- Earning Date
- INAB 08-07-2025
- EQ 08-07-2025
- Dividend Yield
- INAB N/A
- EQ N/A
- EPS Growth
- INAB N/A
- EQ N/A
- EPS
- INAB N/A
- EQ N/A
- Revenue
- INAB N/A
- EQ $30,406,000.00
- Revenue This Year
- INAB N/A
- EQ N/A
- Revenue Next Year
- INAB N/A
- EQ N/A
- P/E Ratio
- INAB N/A
- EQ N/A
- Revenue Growth
- INAB N/A
- EQ N/A
- 52 Week Low
- INAB $2.05
- EQ $0.27
- 52 Week High
- INAB $26.39
- EQ $1.50
- Technical
- Relative Strength Index (RSI)
- INAB 38.73
- EQ 53.38
- Support Level
- INAB $2.12
- EQ $0.37
- Resistance Level
- INAB $2.57
- EQ $0.47
- Average True Range (ATR)
- INAB 0.14
- EQ 0.05
- MACD
- INAB 0.04
- EQ 0.00
- Stochastic Oscillator
- INAB 7.24
- EQ 50.43
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.
About EQ Equillium Inc.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.